Clinical Trials
121 trialsStereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NRG Oncology
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
BR Male
Helios University Hospital Wuppertal
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
Memorial Sloan Kettering Cancer Center
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Providence Health & Services
Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk
Spanish Breast Cancer Research Group
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
University of Chicago
BCCR
University of Nebraska
GEM
Georgetown University
PePPy
Wake Forest University Health Sciences
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors
Vanderbilt University
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Ohio State University Comprehensive Cancer Center
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Bicalutamide in Treating Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
University of South Florida
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery
University of Texas Southwestern Medical Center
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
Case Comprehensive Cancer Center
CP-724,714 in Treating Patients With Metastatic Breast Cancer
Jonsson Comprehensive Cancer Center
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
Jonsson Comprehensive Cancer Center
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Abramson Cancer Center at Penn Medicine
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
University of Washington
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
University of Washington
Capecitabine in Treating Patients With Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
University of Washington
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Jonsson Comprehensive Cancer Center
Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
University of Maryland, Baltimore
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
Wake Forest University Health Sciences
Beverly1
UNICANCER
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Alliance for Clinical Trials in Oncology
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
University of Washington
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
E-MOSAIC Electronic Tool to Monitor Symptoms
Swiss Cancer Institute
F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer
Swiss Cancer Institute
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
University of Washington
BMS-247550
Albert Einstein College of Medicine
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Mayo Clinic
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MALE
GBG Forschungs GmbH
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
University of Chicago
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
University of Washington